NewslettersPulmonary Cell NewsDurable Responses to Alectinib in Murine Models of EML4-ALK Lung Cancer Requires Adaptive ImmunityBy Jamie Kang - February 8, 20230166Investigators used three murine models of EML4-ALK lung cancer to test the role of host immunity in the alectinib therapeutic response.[Npj Precision Oncology]Full Article